AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Insider Transactions Reported | Halozyme Therapeutics(HALO)saw insider trading activity on 7/10/2025
ByAinvest
Thursday, Jul 10, 2025 10:00 pm ET1min read
Halozyme Therapeutics(HALO) saw insider trading activity on 7/10/2025, there were 9 insider trades during the day.
【History Insider Transaction】
| Declare date | Position | Name | Buy/Sell | Quantity | Price per share/USD | Total Amount/USD |
|---|---|---|---|---|---|---|
| 7/10/2025 | PRESIDENT AND CEO | Torley Helen | Sell | 4254 | 56.74 | 241.38k |
| 7/10/2025 | PRESIDENT AND CEO | Torley Helen | Sell | 16402 | 55.74 | 914.21k |
| 7/10/2025 | PRESIDENT AND CEO | Torley Helen | Sell | 19792 | 56.43 | 1116.78k |
| 7/10/2025 | PRESIDENT AND CEO | Torley Helen | Sell | 3598 | 54.48 | 196.03k |
| 7/10/2025 | PRESIDENT AND CEO | Torley Helen | Sell | 208 | 57.08 | 11.87k |
| 7/10/2025 | PRESIDENT AND CEO | Torley Helen | Sell | 15746 | 57.62 | 907.24k |
| 7/10/2025 | PRESIDENT AND CEO | Torley Helen | Buy | 60000 | 8.11 | 486.6k |
| 6/24/2025 | PRESIDENT AND CEO | Torley Helen | Sell | 20000 | 52.96 | 1059.2k |
| 6/24/2025 | PRESIDENT AND CEO | Torley Helen | Sell | 20000 | 52.57 | 1051.46k |
| 6/24/2025 | PRESIDENT AND CEO | Torley Helen | Sell | 4489 | 53.11 | 238.41k |
[Company Profile]
Halozyme Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. The company's research targets the extracellular matrix, an area outside the cell that provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. Over many years, the company has developed unique scientific expertise that allows it to pursue this target-rich environment for the development of future therapies.
The company was founded in 1998 and reincorporated from the State of Nevada to the State of Delaware in November 2007.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet